Covid vaccine Covaxin supply through UN procurement agencies suspended by WHO

In a statement issued by the organisation on Saturday, the suspension has been carried out in response to the outcomes of its post EUL (emergency use authorisation) inspection, which was held between March 14 and 22, 2022 and the need to conduct process and facility upgrade to address recently identified GMP (good manufacturing practice) deficiencies. Due to suspension of production for export, there will be interruption in supply of Covaxin, WHO said. The risk assessment to date does not show change in the risk-benefit ratio. The data, which is available to WHO, shows the vaccine is still effective and there is no safety concern, WHO said.